Le Lézard
Classified in: Health, Science and technology
Subject: Product/Service

SEQENS Is Unveiling Its Main Innovation and Development Centre


A 34,000-square-metre science platform, SEQENS'Lab offers a unique ecosystem, dedicated to our customers to accelerate their projects from the early research and development stages to commercial scale production. Close to Paris, SEQENS'Lab is the centre of excellence for developing a totally unique package of R&D services.

SEQENS'Lab is a development accelerator, dedicated to our customers

As an R&D centre that meets the highest standards, SEQENS'Lab has assembled the group's key skills and expertise in recognised areas of excellence such as: organic chemistry development at the forefront of the latest innovations, two referring laboratories in Physics & Solid-State Chemistry as well as in Process Safety, kinetic and thermodynamic simulation tools, large batch manufacturing capabilities for preclinical and clinical studies, all in an environment that adheres to cGMP.

Furthermore, it has innovative means for developing future processes, particularly in flow chemistry, that are more productive and energy-efficient and have minimal environmental impact.

Innovative SMEs and start-ups that are specialised in analytical services and CROs will be hosted at SEQENS'Lab, giving our customers access to complementary skills in one place. The example of GenEvolution demonstrates this: partner from the very beginning, it brings key skills to SEQENS'Lab in toxicology for medicine, chemical ingredients, plant extracts and cosmetic ingredient evaluation thanks to the miniaturization of its in-vitro tests.

SEQENS'Lab is an appealing and modern place, it reflects the group's development dynamic

"The SEQENS' Lab will also welcome external resources, innovative start-ups and our historic partners, forming a dynamic and cohesive ecosystem in service of innovation. We also want to facilitate interactions with our academic partners and create a LabCom with CNRS (French National Centre for Scientific Research) to design and develop highly innovative solutions," added Christophe Eychenne-Baron, R&D director.

About SEQENS

SEQENS is an integrated global leader in pharmaceutical synthesis and specialty ingredients.

With 24 manufacturing sites and 3 R&D centers in Europe, North America and Asia, SEQENS develops custom solutions and ingredients for the most demanding industries such as healthcare, electronics, cosmetics, food and homecare.

www.seqens.com


These press releases may also interest you

at 14:35
Ossium Health, an innovative bioengineering company that established a first-of-its-kind bone marrow bank, announced today the launch of a new program that further expands patient access to Ossium's bone marrow. Through the HOPE (HPC Offered for...

at 14:22
As we continue to foster economic growth and build Canada's clean economy, significant investments and progress are being made in the production, distribution, and use of clean fuels, including low-carbon hydrogen. These advancements are guided by...

at 14:01
Midea, the world's largest producer of major appliances and a leading innovator in the HVAC industry, announced the launch of its EVOX G3 heat pump system. This latest generation of the EVOX series, featuring the EVOX G3 Heat Pump and EVOX G3 Air...

at 14:00
Canada's pollution pricing system creates incentives for industries to reduce their greenhouse gas emissions, drives innovation and sustainable business practices, and fosters a cleaner, more environmentally responsible future. Through the...

at 14:00
Making the switch to an electric vehicle (EV) is a win-win for families looking to save money while reducing pollution. Due to cheaper refuelling and lower maintenance costs, most EVs cost less than their gas engine counterparts over their lifetime....

at 13:45
Piramal Pharma Limited (NSE: PPLPHARMA) (BSE: 543635), a leading global pharmaceuticals company, today announced its standalone and consolidated results for the Fourth Quarter (Q4) and Full Year (FY) ended 31st March 2024.     Consolidated Financial...



News published on and distributed by: